C. Mackall
Immunology · 2005–2022
A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 102 citations into it
Whom C. Mackall trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts C. Mackall overall
Papers from C. Mackall's perspective
Ordered by how strongly the researchers C. Mackall trusts endorse each paper. Same corpus, a different order for every researcher.
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
- Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate… (Journal of Clinical Oncology)
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. (The Lancet Oncology)
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (New England Journal of Medicine)
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. (Blood)
- CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (Nature Medicine)
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (Journal of Clinical Investigation)
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (New England Journal of Medicine)
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. (Blood)
- IL-7 is critical for homeostatic proliferation and survival of naïve T cells (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (2011) — 1,605 citations
- Tumor Antigen Escape from CAR T-cell Therapy. (2018) — 953 citations
- GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas (2022) — 669 citations
- c-Jun overexpression in CAR T cells induces exhaustion resistance (2019) — 763 citations
- CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL (2017) — 1,111 citations
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy (2015) — 1,165 citations
- 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors (2015) — 1,618 citations
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2014) — 2,727 citations
- Current concepts in the diagnosis and management of cytokine release syndrome. (2014) — 2,536 citations
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy (2014) — 705 citations
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. (2013) — 560 citations
- The Many Faces of IL-7: From Lymphopoiesis to Peripheral T Cell Maintenance (2005) — 628 citations